Marc Wilson
Fortuna: 4 M $ al 30/06/2026
Fortuna: 4 M $ al 30/06/2026
Marc J.
S.
Wilson formerly worked at Trius Therapeutics, Inc., as Accounting Director & Controller from 2010 to 2014, Cidara Therapeutics, Inc., as Chief Accounting Officer & Vice President from 2014 to 2018, and Crinetics Pharmaceuticals, Inc., as Chief Financial Officer from 2018 to 2025.
Mr. Wilson received his undergraduate degree from College of the Holy Cross (Massachusetts).
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 08/07/2026 | 105.237 ( 0,1 % ) | 4 M $ | 30/06/2026 |
| Empresas | Cargo | Fin |
|---|---|---|
| CRINETICS PHARMACEUTICALS, INC. | Director Financiero/CFO | 28/02/2025 |
| CIDARA THERAPEUTICS | Comptroller/Controller/Auditor | 03/01/2018 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops antibacterial drugs for the treatment of infections | Comptroller/Controller/Auditor | 01/08/2014 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 4 |
|---|---|
College of the Holy Cross (Massachusetts)
College of the Holy Cross (Massachusetts) Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops antibacterial drugs for the treatment of infections | Health Technology |
Cidara Therapeutics, Inc.
Cidara Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Engages in the discovery, development, and commercialization of novel anti-infectives | Health Technology |
Crinetics Pharmaceuticals, Inc.
Crinetics Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets therapeutics for endocrine-related diseases | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.